Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

The two largest health insurers in Massachusetts are effectively telling the drug companies that they may seek a rapidly ...

Fibromyalgia patients taking GLP-1s have lower rates of opioid use, pain, fatigue, and malaise in a real-world patient data ...

Walmart's valuation may be overhyped amidst industry headwinds and risks like SNAP cuts, tariffs, and shifting consumer ...

Weight loss medications can reduce the efficacy of oral contraceptives. What to know before taking drugs like Ozempic, ...

Some online pharmacies sell semaglutide and tirzepatide that are ineffective, unsafe, or an outright scam. Here’s how to find ...

See how GLP-1 drugs reduce heart and kidney complications in MGUS and diabetes—explore the clinical evidence. Keep reading!

There’s no doubt that GLP-1 drugs like Ozempic have been revolutionary — although the benefits do sometimes come with some ...

Rybelsus, the oral form of Semaglutide launched by Novo Nordisk in January 2022, has grown from Rs 26 crore to Rs 412 crore, ...

Researchers say GLP-1 medicines might be able to help with migraines.

Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...